<DOC>
	<DOCNO>NCT01918709</DOCNO>
	<brief_summary>Primary objective : To investigate pharmacokinetics concomitant administration valsartan rosuvastatin compare single administration valsartan rosuvastatin healthy male volunteer Secondary objective : To investigate safety profile administration valsartan rosuvastatin alone concomitant administration valsartan rosuvastatin healthy male volunteer</brief_summary>
	<brief_title>Drug Interaction Safety Between Valsartan Rosuvastatin Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Healthy male 20 45 year age screen 2 . 19 kg/m2 ≤ BMI≤ 27 kg/m2 screen 3 . 90 mmHg ≤SBP &lt; 140 mmHg 60 mmHg ≤DBP &lt; 90 mmHg sit position screen 4 . At screen AST ALT ≤ 1.5 time upper normal limit Serum total bilirubin ≤ 1.5 time upper normal limit CK ≤ 2 time upper normal limit 5 . A subject able understand study , participate whole period study provide write informed consent voluntarily fully inform study objective , procedure study drug 1 . A subject medical history clinically significant hepatic , renal , gastrointestinal , respiratory , musculoskeletal , endocrinological , neurologic , hematologic/oncologic , cardiovascular disease 2 . A subject severe renal insufficiency ( CrCL &lt; 10mL/min CockcroftGault estimation ) 3 . A subject history gastrointestinal disease ( e.g. , ulcer , Crohn 's disease ) surgery ( except simple appendectomy repair hernia ) may influence absorption study drug 4 . A subject history drug allergy valsartan , rosuvastatin , drug ( e.g. , aspirin , antibiotic ) , history clinically significant allergy 5 . A subject history drug abuse positive urine drug screen barbiturate , benzodiazepine , methamphetamine , cannabinoids , cocaine , opiate 6 . A subject take prescribed medication herbal compound within 14 day first drug administration . In addition , subject take overthecounter drug vitamin supplement within 7 day first drug administration . ( However , investigator make final decision eligibility trial condition satisfy ) 7 . A subject participate clinical trial receive study drug within 60 day first drug administration 8 . A subject donate unit blood blood component within 60 day 30 day , respectively , receive transfusion first drug administration 9 . A subject take drug inhibits induces drug metabolism barbital 10 . A subject unusual dietary habit may influence administration , distribution , metabolism excretion drug 11 . A subject consumes caffeine excessively ( &gt; 5 units/day ) 12 . A subject consumes alcohol excessively ( &gt; 21 units/week , 1 unit = 10 mL pure alcohol ) history alcoholism 13 . A heavy smoker ( &gt; 10 cigarettes/day ) 14 . A subject positive result serology test ( HBV , HCV , HIV , syphilis ) 15 . A subject hereditary muscle disease family history hereditary muscle disease , history muscle disorder induce drug 16 . The investigator determine whether subject eligible study , example , review clinical laboratory result , ECG result , reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>